Cosentyx is indicated alone or in combination with methotrexate, for the treatment of active PsA in adult patients when the response to previous DMARDs has been inadequate for the treatment of active AS in adults who have responded inadequately to conventional therapy and for the treatment of active nr-axSpA, with objective signs of inflammation, as indicated by elevated C-reactive protein and/or MRI evidence, in adults who have responded inadequately to NSAIDs.
Cosentyx is the first and only fully human targeted IL-17A inhibitor approved for use in PsA and axSpA (nr-axSpA and AS)1
IL-17A is a cornerstone cytokine that plays a critical role at inflammation sites associated with PsA and axSpA indications.2,4
How does Cosentyx inhibit IL-17A?
Watch this short mechanism of action video to understand the rationale for IL-17A inhibition with Cosentyx.
Click here for Cosentyx®(secukinumab) prescribing information
Take the next step
We’re here to support you with dedicated representatives up and down the country. Let us connect you with your local representative to discuss how you can get the most out of Cosentyx.
Or find out more using the links below…
AS, ankylosing spondylitis; axSpA, axial spondyloarthritis; DMARD, disease-modifying antirheumatic drug; IL, interleukin; MRI, magnetic resonance imaging; nr-axSpA, non-radiographic axial spondyloarthritis; NSAID, non-steroidal anti-inflammatory drug; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; PsO, plaque psoriasis.
- Cosentyx Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/3669/smpc (Accessed January 2021).
- Patel DD et al. Ann Rheum Dis. 20 13;72 (suppl. 2):ii116 -23.
- Kirkham B et al. Immunology. 2013;141:133–42.
- Miossec P and Kolls JK. Nat Rev Drug Discov. 2012;11:763–76.
- Spindeldreher S et al. Dermatol Ther (Heidelb). 2018;8:57–68.